07:09 AM EDT, 09/09/2024 (MT Newswires) -- Immunovant ( IMVT ) said on Monday that high doses of its experimental drug batoclimab to treat Graves' Disease significantly reduced IgG levels and improved patient responses compared to lower doses in a phase 2 study.

The study showed that a 680 mg weekly dose led to a 77% reduction in IgG and a 76% response rate, while the 340 mg dose resulted in a 65% IgG reduction and a 68% response rate.

The company plans to commence a pivotal trial of IMVT-1402 in Graves' Disease by December 31, following the U.S. Food & Drug Administration alignment and Investigational New Drug Application clearance.

Price: 34.50, Change: +0.47, Percent Change: +1.38